Evidence map›Paper›PMID 41482379›Full record

ArticleIn vivo (Athens, Greece)

Immunohistochemical Analysis of IRE1 and PERK Expression in Extravillous Trophoblast Cells of Placenta Accreta Spectrum and Associations With Clinicopathological Parameters.

Stefanos Flindris, Konstantinos Christopoulos, Chrysoula Gouta, Christina Yfanti, Nikolaos Tsiaras, Nikoleta-Dimitra Savvidou, Michail Kalinderis, Alexandros Traianos, Apostolos Sidiropoulos, Evangelia Tsakmaki and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Stefanos FlindrisSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece; stefflindris@gmail.com.
Konstantinos Christopoulos *Department of Hygiene and Epidemiology, Medical School, University of Ioannina, Ioannina, Greece.
Chrysoula Gouta *Department of Pathology, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece.
Christina YfantiDepartment of Pathology, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece.
Nikolaos TsiarasDepartment of Pathology, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece.
Nikoleta-Dimitra SavvidouDepartment of Pathology, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece.
Michail KalinderisSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Alexandros TraianosSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Apostolos SidiropoulosSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Evangelia TsakmakiSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Konstantina TsitsilaSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Elif EmpiloukSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Liountmila RomanidouSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Eleni SakellariouDepartment of Pathology, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece.
Konstantinos FlindrisDepartment of Ophthalmology, University Hospital of Ioannina, Medical School, Ioannina, Greece.
Effrosyni StyliaraDepartment of Radiology, University Hospital of Ioannina, Medical School, Ioannina, Greece.
Konstantinos PantazisSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Konstantinos DinasSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Chrysoula Margioula-SiarkouSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Stamatios PetousisSecond Department of Obstetrics and Gynecology of Thessaloniki, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Stamatia AngelidouDepartment of Pathology, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimPlacenta accreta spectrum (PAS) is characterized by abnormal placental adherence/invasion at a scarred implantation bed. Endoplasmic reticulum (ER) stress signaling PATIENTS AND

methodsIn a retrospective series from a tertiary center, cesarean hysterectomy specimens for PAS and gestational age-matched cesarean controls were analyzed. Immunohistochemistry for IRE1 and PERK was performed on basal plate regions, with semiquantitative immunoreactivity score (IRS:0-12) recorded for EVT subtypes. Associations with clinicopathological parameters and with negative controls were examined with bivariate analyses.

resultsIRE1 expression showed no significant associations with clinicopathological parameters. PERK IRS was significantly higher in PAS obstetrical hysterectomy specimens than in controls (mean 9.40±1.96

conclusionPERK-IRS was elevated at the stressed implantation interface in PAS relative to normal placentation, while IRE1 showed no clear differential signal with the current assay. Paradoxically, within PAS, lower local PERK-IRS signal correlated with complications, suggesting that the magnitude/timing of PERK engagement may influence operative risk. Larger studies incorporating activation-specific markers are warranted to refine biological stratification and prognostication in PAS.

Indexed as

eIF-2 KinaseEndoribonucleasesPlacenta AccretaProtein Serine-Threonine KinasesTrophoblastsAdultBiomarkersCesarean SectionEndoplasmic Reticulum StressExtravillous TrophoblastsFemaleHumansHysterectomyImmunohistochemistryPregnancyRetrospective StudiesBiomarkersEIF2AK3 protein, humaneIF-2 KinaseEndoribonucleasesERN1 protein, humanProtein Serine-Threonine Kinasesendoplasmic reticulum stressextravillous trophoblastimmunohistochemical expressionIRE1PERKPlacenta accreta spectrum

Identifiers

PMID41482379
PMCPMC12764185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.